复星医药(02196.HK)子公司药品注册申请获批

阿斯达克财经
Aug 09

复星医药(02196.HK) 公布,控股子公司上海朝晖关于盐酸多巴酚丁胺注射液的药品注册申请获国家药品监督管理局批准。本次获批适应症用于器质性心脏病时心肌收缩力下降引起的心力衰竭,包括心脏直视手术后所致的低排血量综合征,作为短期支持治疗。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-08-07 16:25。)AASTOCKS新闻

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10